Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Fully automated assays for colorectal cancer, 2/16

February 2016—Biocartis launched two products on its molecular diagnostics platform Idylla. The first offering, the Idylla ctBRAF Mutation Assay, uses blood plasma as a sample. The assay can potentially act as a substitute for tissue biopsy testing in melanoma and colorectal and lung cancers, as well as conditions such as hairy cell leukemia and histiocytosis. It has a turnaround time of approximately 90 minutes with less than one minute of hands-on time.

H&E tissue staining solution, 2/16

February 2016—Roche launched the Ventana HE 600 system, its latest fully automated hematoxylin and eosin tissue staining system designed to enhance patient and technician safety and produce exceptional staining quality.

BioTheranostics raises $32 million, announces spinout, 2/16

February 2016—BioTheranostics announced that it has closed a $32 million financing led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and HealthQuest Capital. As a result of the financing, BioTheranostics will be spun out from BioMérieux, which will remain a minority shareholder, and operate as an independent company.

Mouse monoclonal antibodies, 1/16

January 2016—Bio SB introduced Helicobacter Pylori, MMab, Clone: BSB-37, a new line of mouse monoclonal antibodies for IHC with extensive protein immunogenicity analysis of targeted epitopes, high sensitivity specificity, and low background noise.

VEGF ELISA kit, 1/16

January 2016—Enzo Life Sciences launched a VEGF ELISA kit that provides a quantitative, competitive detection method for measuring melatonin in serum, plasma, and cell culture supernants.

Horizon, Swift partnership, 1/16

January 2016—Swift Biosciences will incorporate Horizon Discovery Group’s human genomic reference standards into its new Accel-Amplicon 56G Oncology Panel for use in research and translational applications.

T2 Bacteria Panel study results, 1/16

January 2016—T2 Biosystems presented data at the AMP annual meeting on its investigational T2Bacteria Panel. The data demonstrate the ability of T2Bacteria to provide rapid and sensitive identification of six sepsis-causing bacteria, directly from whole blood, with limits of detection as low as 1 CFU/mL.

Cystatin C assay, 1/16

January 2016—Beckman Coulter Diagnostics launched its Cystatin C assay for the company’s AU clinical low- to ultra-high-volume family of chemistry systems and Immage 800 immunochemistry systems.

Revised CLSI microbiology document, 1/16

January 2016—The Clinical and Laboratory Standards Institute published a revised document titled “Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria (M45-Ed3).”

Expanded enzyme offering, 1/16

January 2016—Worthington Biochemical announced distribution rights to the Celase GMP compliant enzyme from Cytori Therapeutics. The Celase GMP product offering allows Worthington customers focused on cell isolation studies to facilitate a smooth transition from bench and animal research to downstream clinical applications.

MARKETPLACE

TRENDING